S.V. TUMANYAN^1, 2, T.I. MOISEENKO¹, E.M. FRANTSIANTS¹, E.M. NEPOMNYASCHAYA¹, N.V. CHERNIKOVA¹, V.A. BANDOVKINA¹, N.D. CHERYARINA¹, YA.A. MARKOVA²

 ¹National Medical Research Center for Oncology, Rostov-on-Don

²Rostov State Medical University, Rostov-on-Don

 Contact details:

Tumanyan S.V. — MD. (medicine), Professor, Head of the Department of Anesthesiology and Resuscitation

Address: 25 Rodonitovaya St., Kamyshevakha settlement, Russian Federation, 346715, tel.: +7-903-406-55-85, e-mail: stv53@mail.ru

The purpose is to evaluate the influence of the stage of malignant process on the patterns and mechanisms of systemic inflammatory response in patients with uterine corpus cancer.

Material and methods. Hematologic indices were determined in the blood of 108 patients with endometrioid cancer of the uterine corpus and 20 practically healthy women. Additionally, the mass of total adipose tissue, fat-free mass, and their ratio, as well as the ratio of sagittal diameter of the waist to the thigh, were investigated.

Results. The quantitative increase of hematologic indices was dependent on the stage of the malignant process. The rate of basic metabolism increased, indicating an increase in the body’s energy expenditure in response to tumor growth. This was due to an imbalance in energy expenditure, with an increase in the expenditure of fat mass and a disintegration of fat-free mass in patients.

Conclusion. The use of hematologic and anthropometric indices is recommended for the assessment of the systemic inflammatory response in patients with uterine corpus cancer, as well as for the development of pathogenetically justified concomitant therapy.

Key words: uterine corpus cancer, basic metabolism, hypermetabolism, hypercatabolism syndrome, total adipose and fat-free tissue weight.

REFERENCES

1. Leyderman I.N., Gritsan A.I., Zabolotskikh I.B. et al. Perioperative nutritional support. Clinical guidelines. Vestnik intensivnoy terapii im. A.I. Saltanova, 2018, no. 3, pp. 5–21 (in Russ.).
2. Kostyuchenko L.N. Detoxification alimentation of palliative oncology patients. Meditsinskiy alfavit, 2020, no. 17, pp. 15–25 (in Russ.).
3. Klochkova I.S., Astaf’eva L.I., Kadashev B.A. et al. Pathogenetic aspects of cachexia syndrome. Ozhirenie i metabolizm, 2020, vol. 17, no. 1, pp. 33–40 (in Russ.).
4. Petruzzelli M., Wagner E.F. Mechanisms of metabolic dysfunction in cancer-associated cachexia. Genes. Dev, 2016, vol. 30 (5), rr. 489–501.
5. Lucijanić M., Stojić J., Atić A. et al. Clinical and prognostic significance of C-reactive protein to albumin ratio in hospitalized coronavirus disease 2019 (COVID-19) patients: Data on 2309 patients from a tertiary center and validation in an independent cohort. Wien. Klin. Wochenschr, 2022, vol. 134, pp. 377–384.
6. Sarkarova M.R., Maevskaya M.V. Prognostic and diagnostic value of the neutrophil-to-lymphocyte ratio in patients with gastrointestinal tract and liver diseases. Meditsinskiy sovet, 2022, vol. 16, no. 7, pp. 60–68 (in Russ.).
7. Fang T., Wang Y., Yin X. et al. Diagnostic sensitivity of NLR and PLR in early diagnosis of gastric cancer. J. Immunol. Res, 2020, vol. 2020, p. 9146042.
8. Ishibashi Y., Tsujimoto H., Yaguchi Y. et al. Prognostic significance of systemic inflammatory markers in esophageal cancer: Systematic review and meta-analysis. Ann. Gastroenterol. Surg, 2019, vol. 4 (1), pp. 56–63.
9. Li K. J., Xia X. F., Su M. et al. Predictive value of lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) in patients with esophageal cancer undergoing concurrent chemoradiotherapy. BMC Cancer, 2019, vol. 19 (1), p. 1004.
10. Stojkovic Lalosevic M., Pavlovic Markovic A., Stankovic S. et al. Combined diagnostic efficacy of neutrophil-to-lymphocyte ratio (nlr), platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV) as biomarkers of systemic inflammation in the diagnosis of colorectal cancer. Dis. Markers, 2019, vol. 2019, p. 6036979.
11. Tong Y.S., Tan J., Zhou X.L. et al. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J. Transl. Med, 2017, vol. 15 (1), p. 221.
12. Yamamoto T., Kawada K., Obama K. Inflammation-related biomarkers for the prediction of prognosis in colorectal cancer patients. Int. J. Mol. Sci, 2021, vol. 22 (15), p. 8002.
13. Yodying H., Matsuda A., Miyashita M. et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis. Ann. Surg. Oncol, 2016, vol. 23 (2), pp. 646–654.
14. Ushakova N.D., Rozenko D.A., Tikhonova S.N. et al. Clinical and pathogenetic rationale for the use of therapeutic plasma exchange in the complex of preoperative preparation of patients with non-small cell lung cancer complicated by an inflammatory process. Yuzhno-rossiyskiy onkologicheskiy zhurnal, 2024, vol. 5, no. 1, pp. 6–16 (in Russ.).
15. Schwartz P.B., Poultsides G., Roggin K. et al. PLR and NLR are poor predictors of survival outcomes in sarcomas: a new perspective from the USSC. J. Surg. Res, 2020, vol. 251, pp. 228–238.
16. Kit O.I., Vodolazhskiy D.I., Kutilin D.S. et al. Aberrant transcriptional activity of apoptosis-regulating genes in malignancy of uterine body tissues. Molekulyarnaya meditsina, 2018, vol. 16, no. 1, pp. 25–32 (in Russ.).
17. Sjostrom C.D. Relationships between changes in body composition and changes in cardiovascular risk factor: the SOS Intervention Study. Swedish Obese Subjects. Obesity research, 1997, vol. 5 (6), pp. 519–530.
18. Rabe K., Parhofer M.G., Broedl U. Adipokines and insulin resistance. Mol. Med, 2008, vol. 14 (11–12), pp. 741–751.
19. Berezina A.V., Belyaeva O.D., Bazhenova E.A. et al. Features of fat oxidation during physical activity of varying intensity in patients with abdominal obesity. Problemy endokrinologii, 2010, no. 2, pp. 20–25 (in Russ.).
20. Coussens L.M., Zitvogel L., Palucka A.K. Neutralizing tumor-promotingchronic inflammation: a magic bullet? Science, 2013, vol. 339 (6117), pp. 286–291.